John Davidson, MD
Ophthalmology · Ventura, CANPI 1205870748
Payments from drug & device makers
Across 401 payments — averaging $657.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$95K
- Alcon Research LLC$91K
- Alcon$56K
- Sight Sciences, Inc.$13K
- Rxsight Inc$4K
- Lensar, Inc.$1K
- plus $2K from 15 others
Across 22 payments — averaging $727.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$16K
What the payments were for
- Royalty or licence$9,6207%
- Consulting fees$111,79283%
- Speaking & faculty fees$9801%
- Travel & lodging$7,4576%
- Food & beverage$5,0124%
- Gifts$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 93 | $95,269 |
| Alcon Research LLC | 95 | $91,034 |
| Alcon | 112 | $56,455 |
| Sight Sciences, Inc. | 25 | $13,495 |
| Rxsight Inc | 16 | $4,345 |
| Lensar, Inc. | 2 | $1,250 |
| AbbVie(2 entities) | 7 | $400 |
| Kala Pharmaceuticals, Inc. | 14 | $253 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $197 |
| Sun Pharmaceutical Industries Inc. | 8 | $178 |
| Beaver-visitec International, Inc. | 1 | $145 |
| Bausch & Lomb Americas Inc. | 4 | $100 |
| Apellis Pharmaceuticals, Inc. | 1 | $82 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $66 |
| Harrow Eye, LLC | 3 | $61 |
| Carl Zeiss Meditec USA, Inc. | 1 | $40 |
| Tarsus Pharmaceuticals, Inc. | 1 | $36 |
| Smith+Nephew | 2 | $29 |
| Dutch Ophthalmic, USA | 1 | $25 |
| Biotissue Holdings Inc. | 1 | $19 |
| Oyster Point Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENUITY$21,012
- ORA$13,958
- LenSx$11,330
- OMNI$10,611
- SMART Suite$8,820
- ARGOS$5,880
- AcrySof$4,900
- Systane$4,900
- ILUX$4,900
- Clareon$4,900
- Luxor$4,288
- Verion$4,165
- RXSIGHT CONTACT LENS$4,123
- RXSIGHT INJECTOR CARTRIDGE$4,123
- RXSIGHT INJECTOR HANDPIECE$4,123
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$4,123
- LIGHT ADJUSTABLE LENS (LAL)$3,998
- MARLO$2,940
- OMNI(R) SURGICAL SYSTEM (US)$2,625
- Centurion$1,470
How this compares
$263,496 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 396 | $35,654 |
| ProlensaBromfenac Sodium | 68 | $23,761 |
| Difluprednate | 247 | $23,249 |
| IlevroNepafenac | 48 | $17,582 |
| Prednisolone Acetate | 537 | $14,678 |
| MoxifloxacinMoxifloxacin Hcl | 714 | $13,369 |
| Doxycycline Hyclate | 411 | $9,175 |
| BesivanceBesifloxacin Hcl | 40 | $8,857 |
| InveltysLoteprednol Etabonate | 24 | $7,181 |
| BromsiteBromfenac Sodium | 18 | $4,462 |
| Brimonidine Tartrate | 14 | $2,281 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $1,584 |
| Ketorolac Tromethamine | 62 | $661 |
| Ofloxacin | 64 | $604 |
| Acetazolamide | 43 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance | $197 | $32,618108 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $253 | $7,18124 claims |
| Sun Pharmaceutical Industries Inc.Bromsite | $178 | $4,46218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Ventura
- Aaron NagielVentura$1.1M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.